ACTC announces approval to increase RPE dosage for Stargardt's disease patients in U.S. Trials. Robert Lanze MD ACT's chief scientific officer commented. "We are gratified to be moving to the next stage in both of our SMD trials. We remain very encouraged by the preliminary data in the first SMD patients treated with the lowest dose of RPE cells. We are doubling the number of cells [too 100,000cells]. "
SMD programs have been granted "orphan medicinal product designation in both US & Europe. The stock is up a little. This is good news ACTC is moving forward. Still have a good feeling about this company.
Good luck in this rigged casino,
No comments:
Post a Comment